Bracco and Arrayus Partner to Boost Pancreatic Cancer Drug Delivery Using Focused Ultrasound and Microbubbles

Deal Overview

Bracco Imaging S.A., a global leader in diagnostic imaging, has agreed with Arrayus Technologies Inc., a company focused on advancing cancer treatments. The collaboration aims to leverage Bracco’s microbubble technology in combination with Arrayus’ focused ultrasound therapy platform to enhance drug delivery for pancreatic cancer treatment.

Partnership and Technologies

As part of the agreement, Bracco Imaging will supply Arrayus with microbubbles for use in developing and commercializing their focused ultrasound platform. This combination is designed to increase the permeability of biological barriers, allowing for better uptake of drugs into pancreatic tumors, which are notoriously difficult to treat due to their dense tissue structure.

The partnership holds potential for groundbreaking advances in cancer treatment, aiming to maximize the therapeutic impact of both existing and new drugs. Although financial terms were not disclosed, the companies are expected to share synergies in research and development, with preclinical studies and pilot trials already planned for presentation.